| Literature DB >> 28280293 |
Milton W Musaba1, Mike N Kagawa2, Charles Kiggundu3, Paul Kiondo2, Julius Wandabwa4.
Abstract
Background. A 2013 Cochrane review concluded that the choice of antibiotics for prophylaxis in PROM is not clear. In Uganda, a combination of oral erythromycin and amoxicillin is the 1st line for prophylaxis against ascending infection. Our aim was to establish the current cervicovaginal bacteriology and antibiotic sensitivity patterns. Methods. Liquor was collected aseptically from the endocervical canal and pool in the posterior fornix of the vagina using a pipette. Aerobic cultures were performed on blood, chocolate, and MacConkey agar and incubated at 35-37°C for 24-48 hrs. Enrichment media were utilized to culture for GBS and facultative anaerobes. Isolates were identified using colonial morphology, gram staining, and biochemical analysis. Sensitivity testing was performed via Kirby-Bauer disk diffusion and dilution method. Pearson's chi-squared (χ2) test and the paired t-test were applied, at a P value of 0.05. Results. Thirty percent of the cultures were positive and over 90% were aerobic microorganisms. Resistance to erythromycin, ampicillin, cotrimoxazole, and ceftriaxone was 44%, 95%, 96%, and 24%, respectively. Rupture of membranes (>12 hrs), late preterm, and term PROM were associated with more positive cultures. Conclusion. The spectrum of bacteria associated with PROM has not changed, but resistance to erythromycin and ampicillin has increased.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28280293 PMCID: PMC5322418 DOI: 10.1155/2017/9264571
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Sociodemographic and clinical characteristics (n = 196).
| Characteristic | Frequency (%) |
|---|---|
| Mean age | 25 (16–47) years |
| Referral status | |
| Yes | 54 (27.6) |
| No | 142 (72.4) |
| Gestation age | |
| Extreme preterm (28–31 weeks) | 19 (10) |
| Late preterm (32–36 weeks) | 52 (27) |
| Term (>37 weeks) | 125 (64) |
| Gravidity | |
| Primigravida | 80 (40) |
| 2-3 | 60 (31) |
| >3 | 56 (29) |
| Prior antibiotic use | |
| Yes | 46 (23.5) |
| No | 150 (76.5) |
| Duration of ROM | |
| <12 hrs | 77 (39) |
| 12–24 hrs | 20 (10) |
| >24 hrs | 99 (51) |
Isolates from the positive cervicovaginal cultures.
| Number | |
|---|---|
| Gram negative organism | |
| | 3 |
| | 2 |
| | 1 |
| | 12 |
| | 7 |
| Gram positive organisms | |
| | 1 |
| Coagulase-negative | 9 |
| Coryneform bacteria | 1 |
| | 3 |
| | 13 |
| | 8 |
| | 1 |
| | 1 |
| | 3 |
| | 1 |
| Positive rods isolated | 1 |
|
|
|
Anaerobe. Facultative anaerobe.
Antibiotic sensitivity profile of positive cervicovaginal cultures.
| Antibiotic | Sensitive (%) | Resistant (%) | Intermediate (%) |
|
|---|---|---|---|---|
| Ceftriaxone/cefotaxime | 16 (76) | 5 (24) | 0 |
|
| Cotrimoxazole | 1 (4) | 26 (96) | 0 |
|
| Erythromycin | 15 (56) | 10 (37) | 2 (7) |
|
| Vancomycin | 20 (95) | 1 (5) | 0 |
|
| Chloramphenicol | 23 (62) | 14 (38) | 0 |
|
| Clindamycin | 6 (40) | 7 (47) | 2 (13) |
|
| Ampicillin | 1 (5) | 20 (95) | 0 |
|
| Penicillin G | 9 (38) | 15 (63) | 0 |
|
| Co-amoxiclav | 3 (17) | 15 (83) | 0 |
|
| Tetracycline | 6 (21) | 22 (79) | 0 |
|
| Meropenem | 6 (100) | 0 | 0 |
|
| Ciprofloxacin | 21 (66) | 11 (34) | 0 |
|
| Oxacillin | 1 (7) | 14 (93) | 0 |
|
| Ofloxacin | 4 (80) | 1 (20) | 0 |
|
| Cefazolin | 3 (23) | 9 (69) | 1 (8) |
|
| Cefuroxime | 3 (19) | 13 (81) | 0 |
|
| Gentamicin | 12 (46) | 12 (46) | 2 (8) |
|
| Ceftazidime | 2 (100) | 0 | 0 |
|
| Nitrofurantoin | 1 (100) | 0 | 0 |
|
| Cefotaxime-clavulanic acid | 1 (100) | 0 | 0 |
|
Factors associated with cervicovaginal culture and sensitivity patterns.
| Characteristic | Positive cultures | Negative cultures | Odds ratio (CI) |
|
|---|---|---|---|---|
| Referral status | 0.488 | |||
| Yes | 14 (26%) | 40 (74%) | 0.78 (CI 0.49–1.38) | |
| No | 44 (31%) | 98 (69%) | ||
| Mean maternal BP | 119/74 | 116/75 | Mean = 117/75 | |
| Mean radial pulse | 83 | 85 | Mean = 85 | |
| Mean axillary temp. | 37 | 37 | Mean = 37 | |
| Gestation age (weeks) | ||||
| Extreme preterm (28–31) | 8 (42%) | 11 (58%) | 1.4 (CI 1.3–1.6) | 0.000 |
| Late preterm (32–36) | 16 (31%) | 36 (39%) | ||
| Term (>37) | 34 (27%) | 91 (73%) | ||
| Gravidity | ||||
| Primigravida | 24 (30%) | 56 (70%) | 1.12 (CI 0.77–1.62) | 0.343 |
| 2-3 | 14 (23%) | 46 (77%) | ||
| >3 | 20 (36%) | 36 (64%) | ||
| Duration of ROM | ||||
| <12 | 16 (21%) | 61 (79%) | 1.33 (CI 0.96–1.85) | 0.055 |
| 12–24 | 9 (45%) | 11 (55%) | ||
| >24 | 33 (33%) | 66 (67%) | ||
| HIV serology | ||||
| Negative | 50 (29%) | 123 (71%) | 0.76 (CI 0.30–1.92) | 0.562 |
| Positive | 8 (35%) | 15 (65%) | ||
| Prior antibiotic use | ||||
| Yes | 9 (20%) | 37 (80%) | 0.50 (CI 0.22–1.13) | 0.089 |
| No | 49 (33%) | 101 (67%) | ||
| Prior steroid use | ||||
| Yes | 7 (41%) | 10 (59%) | 1.76 (CI 0.63–4.90) | 0.274 |
| No | 51 (28%) | 128 (72%) | ||
| Regular medication use (ART) | ||||
| Yes | 6 (35%) | 11 (65%) | 1.33 (CI 0.47–3.80) | 0.59 |
| No | 52 (29%) | 127 (71%) | ||
| Mean FHR | ||||
| <120 | 0 (0%) | 2 (100%) | 1.30 (CI 0.37–4.54) | 0.654 |
| 120–160 | 55 (30%) | 129 (70%) | ||
| >160 | 3 (30%) | 7 (70%) | ||
| Gram stain result | ||||
| Positive | 38 (50%) | 38 (50%) | 0.2 (CI 0.10–0.40) | <0.001 |
| Negative | 20 (17%) | 100 (83%) |
Gestation age and cervicovaginal cultures of mothers with PROM.
| Odds ratio |
| 95% CI | ||
|---|---|---|---|---|
| Extreme preterm (28–31) R | 1.0 | |||
| Late preterm (32–36) versus extreme preterm (28–31) | 2.3 | 0.007 | 1.2 | 4.1 |
| Term (>37) versus extreme preterm (28–31) | 2.7 | 0.000 | 1.8 | 4.0 |